Please login to the form below

Not currently logged in
Email:
Password:
I have forgotten my password

commercial execution

This page shows the latest commercial execution news and features for those working in and with pharma, biotech and healthcare.

AstraZeneca escapes pandemic impact as new drugs bolster revenues

AstraZeneca escapes pandemic impact as new drugs bolster revenues

We are retaining our full-year guidance that is underpinned by the focus on commercial execution and an exciting pipeline of new medicines,” he added.

Latest news

  • Cancer drugs and China sustain AZ’s return to growth Cancer drugs and China sustain AZ’s return to growth

    commercial execution”. ... We are also enhancing our commercial units to increase collaboration with our R&D organisation, enabling greater commitment to our main therapy areas; we want AZ to be more agile, collaborative

  • AZ says target of $45bn sales by 2023 still achievable AZ says target of $45bn sales by 2023 still achievable

    a stable of cancer therapies, into commercial successes, he continued. ... Commercial execution has been exceptional and our new medicines are now firmly established as the drivers of growth, supporting our continued success in emerging markets,” said

  • Sandoz targets digital therapeutics Sandoz targets digital therapeutics

    Sandoz has a demonstrated record of successful commercial execution both in the US and globally, has extensive expertise working with clinicians and patients, and will provide a dedicated sales force to ... In addition to an upfront payment, the deal

  • GSK’s R&D head Vallance departs, possibly for government role GSK’s R&D head Vallance departs, possibly for government role

    While CEO-designate Walmsley appointed Luke Miels, previously head of AstraZeneca’s EU operations, to take the lead on development at the company, pointing to his “strong record of commercial execution”

  • GSK to sell off part of its HIV venture ViiV Healthcare GSK to sell off part of its HIV venture ViiV Healthcare

    GSK's CEO Andrew Witty said ViiV had made “very significant progress in both R&D and commercial execution”, as seen with the success of Tivicay and Triumeq. ... No job cut figures were mentioned, but the company expects to save £1bn over the next

More from news
Approximately 0 fully matching, plus 7 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 5 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 1 fully matching, plus 4 partially matching documents found.

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Wisepress

Wisepress is a medical bookseller promoting and selling books worldwide, both online and via the 200 European medical conferences that...

Latest intelligence

Mistrust in medical research: a patient perspective
The recent development of several COVID-19 vaccines has placed medical research firmly in the spotlight, highlighting public confusion and misinformation about clinical trials. Patient advocate, Trishna Bharadia reveals what the...
Real-world evidence: breaking boundaries in rare disease
Generating data for drug launches is a challenging process. In rare diseases, with small patient populations and high unmet need, evidence generation is even more complex. Consultant Sarah Poole and...
The heavy toll of COVID-19 on cancer patients
We all know that finding and treating cancer early saves lives. During the COVID-19 pandemic, oncology treatments paused while cancer continued to spread. So, what has been the impact of...

Quick links

Infographics

Multimedia